These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22941473

  • 1. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
    Kim J, Kim SH.
    Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473
    [Abstract] [Full Text] [Related]

  • 2. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K.
    Cancer Res; 2010 Dec 15; 70(24):10288-98. PubMed ID: 21159648
    [Abstract] [Full Text] [Related]

  • 3. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A, Roolf C, Hamed M, Gladbach YS, Sender S, Konkolefski C, Knübel G, Sekora A, Fuellen G, Vollmar B, Murua Escobar H, Junghanss C.
    BMC Cancer; 2019 Mar 06; 19(1):202. PubMed ID: 30841886
    [Abstract] [Full Text] [Related]

  • 4. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
    Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.
    Mol Cancer Ther; 2012 Apr 06; 11(4):994-1005. PubMed ID: 22267551
    [Abstract] [Full Text] [Related]

  • 5. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
    Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JK, Ryckman DM, Anderes K, Rice WG, Drygin D.
    Cancer Lett; 2012 Sep 01; 322(1):113-8. PubMed ID: 22387988
    [Abstract] [Full Text] [Related]

  • 6. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A, Sender S, Lenz A, Schwarz R, Hinz B, Knuebel G, Sekora A, Murua Escobar H, Junghanss C, Roolf C.
    BMC Cancer; 2020 Mar 04; 20(1):184. PubMed ID: 32131762
    [Abstract] [Full Text] [Related]

  • 7. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K.
    Mol Cell Biochem; 2011 Oct 04; 356(1-2):37-43. PubMed ID: 21755459
    [Abstract] [Full Text] [Related]

  • 8. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F, Huang X, Wu M, Gou S, Hu W.
    Cancer Lett; 2017 Jan 28; 385():168-178. PubMed ID: 27793693
    [Abstract] [Full Text] [Related]

  • 9. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW, So KS, Kim SC, Park KM, Lee YJ, Kim SW, Choi CM, Rho JK, Choi YJ, Lee JC.
    Pancreas; 2017 Apr 28; 46(4):575-581. PubMed ID: 28196025
    [Abstract] [Full Text] [Related]

  • 10. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS, Rho JK, Choi YJ, Kim SY, Choi CM, Chun YJ, Lee JC.
    Anticancer Res; 2015 Mar 28; 35(3):1537-42. PubMed ID: 25750308
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
    Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T, Komiya S.
    Oncol Rep; 2017 Feb 28; 37(2):1141-1147. PubMed ID: 27959425
    [Abstract] [Full Text] [Related]

  • 12. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, Bredel M, Benveniste EN.
    Clin Cancer Res; 2013 Dec 01; 19(23):6484-94. PubMed ID: 24036851
    [Abstract] [Full Text] [Related]

  • 13. Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells.
    Guerra B, Rasmussen TD, Schnitzler A, Jensen HH, Boldyreff BS, Miyata Y, Marcussen N, Niefind K, Issinger OG.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):751-61. PubMed ID: 25449433
    [Abstract] [Full Text] [Related]

  • 14. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
    Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, Beom SH, Kim HS, Cheong JH, Chung HC, Soong J, Lin SC, Rha SY.
    Gastric Cancer; 2019 Nov 28; 22(6):1153-1163. PubMed ID: 31098863
    [Abstract] [Full Text] [Related]

  • 15. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
    Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z.
    Int J Biol Sci; 2015 Nov 28; 11(4):411-22. PubMed ID: 25798061
    [Abstract] [Full Text] [Related]

  • 16. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E, Nunes SC, Zaffino F, Casellato A, Macaccaro P, Tubi LQ, Visentin A, Trentin L, Semenzato G, Piazza F.
    Curr Cancer Drug Targets; 2018 Nov 28; 18(6):608-616. PubMed ID: 28460620
    [Abstract] [Full Text] [Related]

  • 17. Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition.
    Wang Y, Lv Z, Chen F, Wang X, Gou S.
    J Med Chem; 2021 Apr 22; 64(8):5082-5098. PubMed ID: 33834781
    [Abstract] [Full Text] [Related]

  • 18. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
    So KS, Kim CH, Rho JK, Kim SY, Choi YJ, Song JS, Kim WS, Choi CM, Chun YJ, Lee JC.
    PLoS One; 2014 Apr 22; 9(12):e114000. PubMed ID: 25486409
    [Abstract] [Full Text] [Related]

  • 19. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.
    Intemann J, Saidu NE, Schwind L, Montenarh M.
    Cell Signal; 2014 Jul 22; 26(7):1567-75. PubMed ID: 24686080
    [Abstract] [Full Text] [Related]

  • 20. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    Kim HM, Jeong I, Kim HJ, Kang SK, Kwon WS, Kim TS, Park KH, Jung M, Soong J, Lin SC, Chung HC, Rha SY.
    Anticancer Res; 2018 Nov 22; 38(11):6171-6180. PubMed ID: 30396934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.